HJC0152

Research use only, not for human use.

A potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo.

A potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis; potently inhibits MCF-7, MDA-MB-231, AsPC1 and Panc-1a cell with IC50 of 0.91, 1.64, 1.9 and 1.08 uM, respectively; suppresses HNSCC cell proliferation, arrests the cell cycle at the G0-G1 phase, induces apoptosis and reduces cell invasion in both SCC25 and CAL27 cell lines; inhibits nuclear translocation of phosphorylated STAT3 at Tyr705 and decreases VHL/β-catenin signaling activity via regulation of miR-21; suppresses MDA-MB-231 xenograft tumor growth in vivo.

HJC-0152;HJC 0152

JAK/STAT Signaling

STAT

STAT3

——

——

1420290-99-8

406.64

C15H14Cl3N3O4

>98% (HPLC)

DMSO: 82 mg/mL (201.7 mM) （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2OCCN.[H]Cl

2-(2-aminoethoxy)-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide hydrochloride

(-20℃)

With Ice Pack

≥ 2 years